Follow
Emily Karanges
Emily Karanges
Unknown affiliation
Verified email at psych.usyd.edu.au
Title
Cited by
Cited by
Year
Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011
CP Stephenson, E Karanges, IS McGregor
Australian & New Zealand Journal of Psychiatry 47 (1), 74-87, 2013
2982013
The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers
L Mellish, EA Karanges, MJ Litchfield, AL Schaffer, B Blanch, BJ Daniels, ...
BMC research notes 8, 1-13, 2015
2742015
Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats
C Klein, E Karanges, A Spiro, A Wong, J Spencer, T Huynh, ...
Psychopharmacology 218, 443-457, 2011
2322011
Twenty‐five years of prescription opioid use in Australia: a whole‐of‐population analysis using pharmaceutical claims
EA Karanges, B Blanch, NA Buckley, SA Pearson
British journal of clinical pharmacology 82 (1), 255-267, 2016
1852016
Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey
EA Karanges, A Suraev, N Elias, R Manocha, IS McGregor
BMJ open 8 (7), e022101, 2018
1352018
Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009–2012: Focus on children, adolescents and prescriber specialty
EA Karanges, CP Stephenson, IS McGregor
Australian & New Zealand Journal of Psychiatry 48 (10), 917-931, 2014
1142014
Psychotropic medication use in Australia, 2007 to 2015: changes in annual incidence, prevalence and treatment exposure
J Brett, EA Karanges, B Daniels, NA Buckley, C Schneider, A Nassir, ...
Australian & New Zealand Journal of Psychiatry 51 (10), 990-999, 2017
762017
Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion
CP Motbey, E Karanges, KM Li, S Wilkinson, AR Winstock, J Ramsay, ...
Public Library of Science 7 (9), e45473, 2012
642012
Trends in self-poisoning and psychotropic drug use in people aged 5–19 years: a population-based retrospective cohort study in Australia
R Cairns, EA Karanges, A Wong, JA Brown, J Robinson, SA Pearson, ...
BMJ open 9 (2), e026001, 2019
562019
Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents?
E Karanges, KM Li, C Motbey, PD Callaghan, A Katsifis, IS McGregor
International Journal of Neuropsychopharmacology 14 (4), 491-504, 2011
472011
Trends in opioid utilisation in Australia, 2006‐2015: insights from multiple metrics
EA Karanges, NA Buckley, J Brett, B Blanch, M Litchfield, L Degenhardt, ...
Pharmacoepidemiology and drug safety 27 (5), 504-512, 2018
462018
To what extent do data from pharmaceutical claims under‐estimate opioid analgesic utilisation in Australia?
N Gisev, SA Pearson, EA Karanges, B Larance, NA Buckley, S Larney, ...
Pharmacoepidemiology and drug safety 27 (5), 550-555, 2018
452018
Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study
J Brett, B Daniels, EA Karanges, NA Buckley, C Schneider, A Nassir, ...
British journal of clinical pharmacology 83 (11), 2581-2588, 2017
382017
Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study
L Parker, EA Karanges, L Bero
BMJ open 9 (2), e024928, 2019
322019
Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of “paradoxical” antidepressant …
EA Karanges, MA Kashem, R Sarker, EU Ahmed, S Ahmed, ...
Frontiers in pharmacology 4, 86, 2013
262013
Antidepressants and adolescent brain development
E Karanges, IS McGregor
Future Neurology 6 (6), 783-808, 2011
242011
Pharmaceutical industry payments to leaders of professional medical associations in Australia:'Focus on cardiovascular disease and diabetes'
EA Karanges, N Ting, L Parker, A Fabbri, L Bero
Australian Journal of General Practice 49 (3), 151-154, 2020
162020
Understanding the nature and extent of pharmaceutical industry payments to nonphysician clinicians
EA Karanges, Q Grundy, L Bero
JAMA Internal Medicine 179 (10), 1430-1432, 2019
132019
Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study
B Behdarvand, EA Karanges, L Bero
BMJ open 9 (8), e030253, 2019
132019
The changing face of Australian data reforms: impact on pharmacoepidemiology research
J de Oliveira Costa, C Bruno, AL Schaffer, S Raichand, EA Karanges, ...
International journal of population data science 6 (1), 2021
112021
The system can't perform the operation now. Try again later.
Articles 1–20